Dr. Reddy's Laboratories Ltd. announced unaudited standalone and consolidated earnings results for the third quarter and nine months ended December 31, 2017. For the quarter, on standalone basis, the company reported net sales/income from operations of INR 24,873 million against INR 25,442 million a year ago. Profit before tax was INR 3,716 million against INR 5,294 million a year ago. Net profit for the period was INR 2,969 million or INR 17.87 per diluted share before and after extraordinary items against INR 4,388 million or INR 26.44 per diluted share before and after extraordinary items a year ago. Total income was INR 25,707 million against INR 26,575 million a year ago For the nine months, on standalone basis, the company reported net sales/income from operations of INR 67,974 million against INR 73,008 million a year ago. Total income was INR 69,979 million against INR 78,929 million a year ago. Profit before tax was INR 5,016 million against INR 13,811 million a year ago. Net profit for the period was INR 3,903 million or INR 23.49 diluted per share before and after extraordinary items against INR 11,611 million or INR 69.38 diluted per share before and after extraordinary items a year ago. For the quarter, on consolidated basis, the company reported net sales/income from operations of INR 39,164 million against INR 36,534 million a year ago. Total income was INR 38,771 million against INR 37,635 million a year ago. Profit before tax was INR 5,470 million against INR 6,219 million a year ago. Net profit for the period was INR 2,942 million or INR 18.22 per diluted share before and after extraordinary items against INR 4,834 million or INR 29.65 per diluted share before and after extraordinary items a year ago. EBITDA was 80.6 million. For the nine months, on consolidated basis, the company reported net sales/income from operations of INR 103,558 million against INR 103,678 million a year ago. Total income was INR 108,374 million against INR 107,352 million a year ago. Profit before tax was INR 10,360 million against INR 12,166 million a year ago. Net profit for the period was INR 6,472 million or INR 40.61 per diluted share before and after extraordinary items against INR 9,299 million or INR 57.04 per diluted share before and after extraordinary items a year ago. EBITDA was 183.0 million.